Vaccine Developments: Pfizer seeks approval for storage at higher temperatures, J&J seeks WHO approval
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
RICHMOND, Va. — When tiny glass vials of coronavirus vaccine began rolling off production lines late last year, federal health officials set aside a big stash for nursing homes being ravaged by the virus. Health providers around the country figured as well that it was prudent to squirrel away vials to ensure that everyone who got a first dose of vaccine got a second one.
Two months later, it is clear both strategies went overboard.
Submitted by mike kraft on
All across Europe, coronavirus vaccines are in scarce supply. But in France, they are also surprisingly unwanted: Recent polls suggest just 57% of the country intends to get vaccinated, whereas in the United Kingdom, 89% wants to get a shot for COVID-19.
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Teenagers contract the novel coronavirus almost twice as often as younger children but vaccines authorized in the United States are mostly for adults — Moderna’s for 18 and older, Pfizer’s for 16 and up.
Submitted by mike kraft on
Submitted by mike kraft on